Bicocca Open Archive

Logo unimib boa
INVERNIZZI, PIETRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.559
AS - Asia 19.376
EU - Europa 17.493
SA - Sud America 2.918
Continente sconosciuto - Info sul continente non disponibili 1.887
AF - Africa 493
OC - Oceania 28
Totale 74.754
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.703
SG - Singapore 6.868
IT - Italia 5.415
CN - Cina 3.586
SE - Svezia 3.356
HK - Hong Kong 2.868
VN - Vietnam 2.750
RU - Federazione Russa 2.232
BR - Brasile 2.184
DE - Germania 1.731
CA - Canada 1.500
IE - Irlanda 1.288
BD - Bangladesh 806
GB - Regno Unito 776
FR - Francia 618
IN - India 492
AT - Austria 361
UA - Ucraina 354
FI - Finlandia 336
AR - Argentina 304
ID - Indonesia 286
TR - Turchia 255
KR - Corea 246
NL - Olanda 221
IQ - Iraq 210
ES - Italia 157
CH - Svizzera 156
ZA - Sudafrica 149
JP - Giappone 148
MX - Messico 142
PK - Pakistan 133
PL - Polonia 117
PH - Filippine 111
SA - Arabia Saudita 110
EC - Ecuador 96
DK - Danimarca 93
CO - Colombia 87
UZ - Uzbekistan 74
MY - Malesia 71
VE - Venezuela 71
MA - Marocco 67
JM - Giamaica 52
BE - Belgio 48
PY - Paraguay 44
CL - Cile 43
DZ - Algeria 43
KE - Kenya 42
EG - Egitto 40
LT - Lituania 38
PE - Perù 36
AE - Emirati Arabi Uniti 35
CR - Costa Rica 35
JO - Giordania 35
IL - Israele 31
TN - Tunisia 29
CZ - Repubblica Ceca 28
ET - Etiopia 28
TW - Taiwan 27
NP - Nepal 26
AZ - Azerbaigian 25
RO - Romania 25
PT - Portogallo 23
GR - Grecia 22
UY - Uruguay 22
AU - Australia 21
BO - Bolivia 21
IR - Iran 21
TT - Trinidad e Tobago 21
PS - Palestinian Territory 20
HN - Honduras 19
TH - Thailandia 19
KZ - Kazakistan 18
LB - Libano 18
AL - Albania 17
OM - Oman 15
PA - Panama 15
SN - Senegal 15
NI - Nicaragua 14
RS - Serbia 13
DO - Repubblica Dominicana 12
SY - Repubblica araba siriana 12
BG - Bulgaria 11
GT - Guatemala 11
NG - Nigeria 11
SK - Slovacchia (Repubblica Slovacca) 11
SV - El Salvador 10
HU - Ungheria 9
MM - Myanmar 8
QA - Qatar 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AO - Angola 7
KG - Kirghizistan 7
LY - Libia 7
NO - Norvegia 7
SC - Seychelles 7
EU - Europa 6
LA - Repubblica Popolare Democratica del Laos 6
MU - Mauritius 6
SR - Suriname 6
BA - Bosnia-Erzegovina 5
Totale 72.746
Salva come PNG Salva come JPEG
Città #
Singapore 4.046
Ann Arbor 3.833
Hong Kong 2.794
Ashburn 2.755
Stockholm 1.908
San Jose 1.854
Fairfield 1.778
Milan 1.691
Woodbridge 1.346
Dublin 1.235
Toronto 1.155
Chandler 1.145
Frankfurt am Main 1.084
Wilmington 1.040
Houston 1.032
New York 904
Chicago 838
Ho Chi Minh City 796
Seattle 796
Council Bluffs 694
Santa Clara 674
Los Angeles 657
Hanoi 632
Cambridge 623
Dallas 593
Dearborn 501
Rome 481
Princeton 480
Beijing 476
The Dalles 453
Hefei 450
Jacksonville 382
Boardman 324
Lauterbourg 297
Vienna 277
London 252
Buffalo 249
Lawrence 229
Seoul 227
Shanghai 220
Columbus 219
Nanjing 218
Moscow 216
Altamura 213
São Paulo 209
Jakarta 201
Helsinki 198
San Diego 146
Zurich 132
Orem 130
Nuremberg 119
Munich 116
Turin 110
Tokyo 106
Guangzhou 98
Haiphong 97
Da Nang 94
Florence 87
Figino 85
Rio de Janeiro 85
Brooklyn 84
Montreal 81
Naples 80
Atlanta 78
Dong Ket 78
Phoenix 77
Johannesburg 75
Denver 71
Warsaw 70
Andover 68
Baghdad 68
Bologna 65
Monza 63
Lachine 62
Salt Lake City 62
Tashkent 61
Biên Hòa 60
Hangzhou 60
Washington 58
Bari 56
Chennai 55
Nanchang 55
Changsha 54
Boston 53
San Francisco 53
Dhaka 52
Amsterdam 49
Ottawa 48
Tampa 47
Istanbul 46
Belo Horizonte 45
Can Tho 44
Hải Dương 44
Mumbai 44
Pune 44
Shenyang 43
Brussels 42
Tianjin 42
Elk Grove Village 41
Hebei 41
Totale 46.399
Salva come PNG Salva come JPEG
Nome #
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial 1.992
Improvements and future perspective in diagnostic tools for neuroendocrine neoplasms 738
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score 608
Validation of the Italian version of fisk fatigue severity score (FFSS) and PBC-40 531
Impact of multidisciplinary team approach to liver tumors in a tertiary center: 5-years experience 500
Dexamethasone Conjugation to Biodegradable Avidin-Nucleic-Acid-Nano-Assemblies Promotes Selective Liver Targeting and Improves Therapeutic Efficacy in an Autoimmune Hepatitis Murine Model 459
Exploring the landscape of steatotic liver disease in the general US population 446
A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude? 437
Quality of life in patients with primary biliary cholangitis: a cross-geographical comparison 420
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 407
A second update on mapping the human genetic architecture of COVID-19 393
Mapping the human genetic architecture of COVID-19 373
Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response 371
Endocrinology and Metabolic Diseases (Including Diabetes) 361
A short version of a HRQoL questionnaire for Italian and Japanese patients with Primary Biliary Cirrhosis 356
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis 352
The liver in Christian thought: Symbolism, morality, and spirituality 351
Knockout of α-calcitonin gene-related peptide attenuates cholestatic liver injury by differentially regulating cellular senescence of hepatic stellate cells and cholangiocytes 350
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs 350
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms 349
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development 349
Accuracy of Liver Stiffness Measurement in assessing liver fibrosis in naïve patients with Primary Biliary Cholangitis 347
Risk stratification in primary sclerosing cholangitis 340
Precision medicine in primary biliary cholangitis 337
Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naïve patients with Primary Biliary Cholangitis: a dual cut-off approach 337
Amelioration of Ductular Reaction by Stem Cell Derived Extracellular Vesicles in MDR2 Knockout Mice via Lethal-7 microRNA 332
Hepatic focal nodular hyperplasia after pediatric hematopoietic stem cell transplantation: The impact of hormonal replacement therapy and iron overload 331
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 327
Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature 327
FRI-008-Incidence, prevalence and mortality of primary sclerosing cholangitis in Italy: A population-based study 326
Understanding short bowel syndrome: Current status and future perspectives 325
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma 319
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma 316
Greater Transplant-Free Survival in Patients Receiving Obeticholic Acid for Primary Biliary Cholangitis in a Clinical Trial Setting Compared to Real-World External Controls 314
Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2−/− mice and human primary sclerosing cholangitis 313
High rates of 30-day mortality in patients with cirrhosis and COVID-19 310
Additive beneficial effects of Fibrates combined with Obeticholic acid in the treatment of patients with Primary Biliary Cholangitis and inadequate response to second-line therapy: data from the Italian PBC Study Group 306
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 306
Dermatological Complications After Solid Organ Transplantation 304
DCLK1, a putative novel stem cell marker in human cholangiocarcinoma 304
FRI-006-Soluble CD163 and mannose receptor as markers of liver disease severity and long term prognosis in patients with primary biliary cholangitis 303
A NOVEL MACHINE-LEARNING, COMMON VARIANTS-BASED APPROACH TO PREDICT PRIMARY BILIARY CHOLANGITIS 301
Autoimmune liver diseases 300
It's as if PBC didn’t exist: The illness experience of women affected by primary biliary cirrhosis 299
Machine learning in primary biliary cholangitis: A novel approach for risk stratification 294
From pathogenesis to novel therapies in the treatment of primary biliary cholangitis 292
THU-010-Shedding light on the X chromosome contribution to the genetic architecture of primary biliary cholangitis 292
Endoscopic Findings in Patients Infected With 2019 Novel Coronavirus in Lombardy, Italy 291
New Therapeutic Targets in Autoimmune Cholangiopathies 290
Immune-mediated drug-induced liver injury: Immunogenetics and experimental models 290
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 285
Better end points needed in primary sclerosing cholangitis trials 285
miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation 284
Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study 284
The changing face of chronic autoimmune atrophic gastritis: an updated comprehensive perspective 283
Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis 282
Clinical treatment of cholangiocarcinoma: an updated comprehensive review 280
The mode of dexamethasone decoration influences avidin-nucleic-acid-nano-assembly organ biodistribution and in vivo drug persistence 279
Artificial Intelligence and liver: Opportunities and barriers 277
The X-factor in primary biliary cirrhosis: Monosomy X and xenobiotics 276
Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the " Cholangiocarcinoma" committee of the Italian Association for the Study of Liver disease 274
Validation of the Japanese version of the Fisk Fatigue Severity Score (FFSS) in Japanese patients with primary biliary cirrhosis 273
Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis 272
Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland 271
Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach 269
Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis 268
Inhibition of the apelin/apelin receptor axis decreases cholangiocarcinoma growth 266
The challenges of primary biliary cholangitis: What is new and what needs to be done 264
The Seat of Life. What a Lesson from the Stigmatized Saints 264
An update on novel pharmacological agents for primary sclerosing cholangitis 263
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 262
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 262
Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies 260
Ductular reaction, intermediate hepatocytes and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 258
Y chromosome loss in male patients with primary biliary cirrhosis 258
Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review 258
Primary biliary cholangitis: a multifaceted pathogenesis with potential therapeutic targets 257
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 253
Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma 253
Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis 252
“I Miss My Liver.” Nonmedical Sources in the History of Hepatocentrism 252
Prognostic models in primary biliary cholangitis 252
Deep learning helps discriminate between autoimmune hepatitis and primary biliary cholangitis 251
Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma 250
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways 250
Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells 250
Artificial intelligence for precision medicine in autoimmune liver disease 249
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? 248
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 248
Geographical region and clinical outcomes of patients with primary biliary cholangitis from Western Europe 247
Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth 247
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth 247
Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis 247
Exploring the spectrum of incidental gastric polyps in autoimmune gastritis 246
AISF position paper on liver disease and pregnancy 244
AB0511 International Consensus on ANCA Testing and Interpretation Beyond Systemic Vasculitis 244
Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis 243
Female preponderance of primary biliary cholangitis is all about our understanding of its autoimmune nature 243
FRI-011-Ductular reaction, intermediate hepatocites and fibrosis extension correlate with prediction of treatment failure to ursodeoxycholic acid in primary biliary cholangitis 243
Coronavirus Disease 2019 (COVID-19) in autoimmune hepatitis: a lesson from immunosuppressed patients 243
Totale 32.582
Salva come PNG Salva come JPEG
Categoria #
all - tutte 255.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 255.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.023 0 274 450 243 204 240 132 212 147 214 312 595
2022/20235.371 601 1.340 437 474 462 807 153 297 443 94 150 113
2023/20244.867 131 159 172 426 549 1.098 753 188 362 248 86 695
2024/202511.516 792 1.268 738 608 973 478 672 489 1.171 1.576 1.039 1.712
2025/202631.579 3.048 1.671 2.080 2.746 2.909 1.496 3.700 1.790 2.493 4.460 2.494 2.692
2026/20273.313 1.481 1.832 0 0 0 0 0 0 0 0 0 0
Totale 74.754